License, Clinical Trial and Sponsored Research Agreements - Additional Information (Details) - USD ($) |
1 Months Ended | ||||
|---|---|---|---|---|---|
Feb. 28, 2019 |
May 31, 2017 |
Feb. 28, 2017 |
May 31, 2019 |
Mar. 31, 2019 |
|
| City of Hope | CS1 License (MB-104) [Member] | |||||
| Payment Of Upfront Fees | $ 600,000 | ||||
| Revenue Recognition Milestone Method Payments Due | 14,900,000 | ||||
| Cost of Goods and Services Sold | $ 50,000 | ||||
| Research And Development Expense, Sponsored Research Payment | $ 200,000 | ||||
| City of Hope | CD123 License (MB-102) [Member] | |||||
| Revenue Recognition Milestone Method Payments Due | $ 14,500,000 | ||||
| Cost of Goods and Services Sold | $ 25,000 | ||||
| Research And Development Expense, Sponsored Research Payment | $ 300,000 | ||||
| Nationwide Children's Hospital - C134 | |||||
| Payment Of Upfront Fees | $ 200,000 | ||||
| Licensing Arrangements Additional Costs Incurred | $ 152,800,000 | ||||
| X | ||||||||||
- Definition Represents the additional costs incurred under licensing arrangement. No definition available.
|
| X | ||||||||||
- Definition Payment of Upfront Fees No definition available.
|
| X | ||||||||||
- Definition The amount of research and development expense payable on achieving milestone targets. No definition available.
|
| X | ||||||||||
- Definition The amount of consideration eligible to receive during the period for the milestone or milestones. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|